SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sofosbuvir; velpatasvir; voxilaprevir and what is the scope of patent protection?
Sofosbuvir; velpatasvir; voxilaprevir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are nineteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sofosbuvir; velpatasvir; voxilaprevir has six hundred and twenty-two patent family members in forty-nine countries.
One supplier is listed for this compound.
Summary for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
| International Patents: | 622 |
| US Patents: | 19 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 18 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR |
| DailyMed Link: | SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
Generic Entry Date for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Peking University People's Hospital | Phase 4 |
| Helwan University | Phase 4 |
| Kirby Institute | Phase 4 |
See all SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR clinical trials
Pharmacology for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovenia | 2552930 | ⤷ Try a Trial | |
| Argentina | 088580 | METODOS Y COMPOSICIONES PARA TRATAR EL VIRUS DE LA HEPATITIS C | ⤷ Try a Trial |
| Spain | 2644990 | ⤷ Try a Trial | |
| Cyprus | 1115488 | ⤷ Try a Trial | |
| Argentina | 089578 | COMPOSICIONES, METODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C Y PROCESO DE PREPARACION | ⤷ Try a Trial |
| Australia | 2012318253 | Antiviral compounds | ⤷ Try a Trial |
| Japan | 6073897 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203462 | 300704 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 2203462 | SPC/GB14/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; REGISTERED: UK EU/1/13/894/001 20140117; UK EU/1/13/894/002 20140117 |
| 2203462 | C 2014 043 | Romania | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894(001-002); DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894(001-002); DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
| 2203462 | 2014029 | Norway | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR. (S)-ISOPROPYL 2-; NAT. REG. NO/DATE: EU/1/13/894 20140116; FIRST REG. NO/DATE: (001-002) 20140117 |
| 2203462 | CR 2014 00061 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140117 |
| 2203462 | 1491066-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/13/894, 2014-01-17 |
| 2203462 | C20140035 | Estonia | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
